Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ginisortamab - Oxford University Innovation/UCB Biopharma/University of Adelaide

Next Previous
Drug Profile

Ginisortamab - Oxford University Innovation/UCB Biopharma/University of Adelaide

Alternative Names: Anti-GREMl antagonist; Anti-Greml antibody UCB6114; Anti-Greml neutralising antibody; Greml-neutralising antibody; UCB-6114

Latest Information Update: 20 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oxford University Innovation; UCB Biopharma; University of Adelaide
  • Developer UCB Biopharma
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Intercellular signalling peptide and protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 11 Apr 2024 UCB Biopharma completes a phase I/II trial in Solid tumours (Monotherapy, Combination therapy, In adults, In the elderly, Late-stage disease, Metastatic disease) in USA and United Kingdom (IV) (NCT04393298) (EudraCT2019-002598-78)
  • 28 Jul 2023 No recent reports of development identified for preclinical development in Solid-tumours in United Kingdom (SC, Injection)
  • 14 Apr 2023 Efficay and adverse events data from phase-I/II trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top